Platelet Rich Plasma Study in Lower Extremity Bypass Surgery - Full Text View

Platelet Rich Plasma Study in Lower Extremity Bypass Surgery (PRP)

This study has been completed.

First Received on August 16, 2007. Last Updated on January 4, 2011 History of Changes

Sponsor:	Lawson Health Research Institute
Collaborator:	Biomet, Inc.
Information provided by:	Lawson Health Research Institute
ClinicalTrials.gov Identifier:	NCT00517452

Purpose

The use of platelet rich plasma will decrease wound infection postop.

Condition	Phase
Atherosclerosis	Phase II Phase III

Study Type:	Observational
Study Design:	Observational Model: Cohort Time Perspective: Prospective
Official Title:	Phase 2-3 Observational Wound Care Study Comparing Application of Platelet Rich Plasma With Standard of Care Wound Closure in Vascular Patients Requiring a Groin Incision.

Resource links provided by NLM:

MedlinePlus related topics: Atherosclerosis

U.S. FDA Resources

Further study details as provided by Lawson Health Research Institute:

Primary Outcome Measures:

Wound healing [ Time Frame: 4- 6 weeks post op ] [ Designated as safety issue: No ]

Enrollment:	81
Study Start Date:	May 2007
Study Completion Date:	December 2007

Groups/Cohorts
Platelet Rich Plasma Group received platelet rich plasma and observed over a period of 30 days or until wound closure
Standard Wound Care Group was treated as per standard care

Eligibility

Ages Eligible for Study:	35 Years to 90 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No
Sampling Method:	Probability Sample

Study Population

Vascular surgical patients scheduled for elective lower extremity bypass surgery,aortoiliac revascularizations and endovascular AAA repair requiring a groin incision

Criteria

Inclusion Criteria:

Vascular surgical patients scheduled for elective lower extremity bypass surgery,aortoiliac revascularizations and endovascular AAA repair requiring a groin incision Exclusion Criteria:Patients requiring emergent procedures, unable to give informed consent

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00517452

Sponsors and Collaborators

Lawson Health Research Institute

Biomet, Inc.

Investigators

Principal Investigator:

Kirk D Lawlor

London Health Sciences Centre, University of Western Ontario

More Information

No publications provided

Responsible Party:	Dr. K. Lawlor, Lawson Health Research Institute
ClinicalTrials.gov Identifier:	NCT00517452 History of Changes
Other Study ID Numbers:	R-07-098
Study First Received:	August 16, 2007
Last Updated:	January 4, 2011
Health Authority:	Canada: Health Canada

Additional relevant MeSH terms:

Atherosclerosis
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases

ClinicalTrials.gov processed this record on February 12, 2012